Antares submits new drug application to FDA for Quickshot Testosterone
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Antares Pharma Inc. submitted a new drug application to the U.S. FDA for its QuickShot Testosterone, a drug-device combination product for treating men with low testosterone associated with hypogonadism.
The product delivers testosterone enanthate using a subcutaneous auto injector.
